BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20131304)

  • 1. Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count.
    Jacobs NL; Holtan SG; Porrata LF; Markovic SN; Tefferi A; Steensma DP
    Am J Hematol; 2010 Mar; 85(3):160-3. PubMed ID: 20131304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
    Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
    Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absolute lymphocyte count predicts overall survival in follicular lymphomas.
    Siddiqui M; Ristow K; Markovic SN; Witzig TE; Habermann TM; Colgan JP; Inwards DJ; White WL; Ansell SM; Micallef IN; Johnston PB; Call TG; Porrata LF
    Br J Haematol; 2006 Sep; 134(6):596-601. PubMed ID: 16889618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study.
    Ege H; Gertz MA; Markovic SN; Lacy MQ; Dispenzieri A; Hayman SR; Kumar SK; Porrata LF
    Br J Haematol; 2008 Jun; 141(6):792-8. PubMed ID: 18410454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.
    Germing U; Lauseker M; Hildebrandt B; Symeonidis A; Cermak J; Fenaux P; Kelaidi C; Pfeilstöcker M; Nösslinger T; Sekeres M; Maciejewski J; Haase D; Schanz J; Seymour J; Kenealy M; Weide R; Lübbert M; Platzbecker U; Valent P; Götze K; Stauder R; Blum S; Kreuzer KA; Schlenk R; Ganser A; Hofmann WK; Aul C; Krieger O; Kündgen A; Haas R; Hasford J; Giagounidis A
    Leukemia; 2012 Jun; 26(6):1286-92. PubMed ID: 22289990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma.
    Porrata LF; Litzow MR; Inwards DJ; Gastineau DA; Moore SB; Pineda AA; Bundy KL; Padley DJ; Persky D; Ansell SM; Micallef IN; Markovic SN
    Bone Marrow Transplant; 2004 Feb; 33(3):291-8. PubMed ID: 14676784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma.
    Joao C; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Gastineau DA; Markovic SN
    Bone Marrow Transplant; 2006 May; 37(9):865-71. PubMed ID: 16532015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis.
    Porrata LF; Gertz MA; Litzow MR; Lacy MQ; Dispenzieri A; Inwards DJ; Ansell SM; Micallef IN; Gastineau DA; Elliott M; Hogan WJ; Hayman SR; Tefferi A; Markovic SN
    Clin Cancer Res; 2005 Feb; 11(3):1210-8. PubMed ID: 15709191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan.
    Tasaka T; Tohyama K; Kishimoto M; Ohyashiki K; Mitani K; Hotta T; Kanamaru A; Okamoto S; Karasawa M; Kimura A; Tomonaga M; Uchiyama T; Ozawa K;
    Leukemia; 2008 Oct; 22(10):1874-81. PubMed ID: 18668133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma: the need to optimize instrument setting and define a lymphocyte collection target.
    Katipamula R; Porrata LF; Gastineau DA; Markovic SN; Moore SB; Greiner C; Burgstaler EA; Padley DJ; Winters JL
    Bone Marrow Transplant; 2006 May; 37(9):811-7. PubMed ID: 16532018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS.
    Slovak ML; O'Donnell M; Smith DD; Gaal K
    Cancer Genet Cytogenet; 2009 Sep; 193(2):78-85. PubMed ID: 19665067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System.
    Mirza I; Garzón R; Burns J; Edwards L; Fernandez-Cymering C; Kloss R
    Conn Med; 2001 Aug; 65(8):455-63. PubMed ID: 11550445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.
    Hui CH; Horvath N; Lewis I; To LB; Szabo F
    Intern Med J; 2008 Nov; 38(11):824-8. PubMed ID: 18284457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes.
    Germing U; Aul C; Niemeyer CM; Haas R; Bennett JM
    Ann Hematol; 2008 Sep; 87(9):691-9. PubMed ID: 18575866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma.
    Kim H; Sohn HJ; Kim S; Lee JS; Kim WK; Suh C
    Bone Marrow Transplant; 2006 Jun; 37(11):1037-42. PubMed ID: 16708062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.